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doi:10.1016/j.ejvs.2011.06.019Abstract Purpose: To study intermediate clinical outcomes, rates of recurrent varicosities
and neovascularisation, ultrasound changes of the GSV, and the quality of life changes in
patients from EVOLVeS trial.
Methods: Forty five patients were re-examined 1 year and 65 two years after treatment.
Follow-up visits included clinical examination with CEAP classification and calculation of
venous clinical severity score (VCSS), ultrasound examination, and a quality of life question-
naire.
Results: The clinical course of the disease (CEAP, VCSS) was similar in the two treatment
groups. 51% of the GSV trunks occluded by RFO underwent progressive shrinkage with the
external diameter decreased from 6.3 SD 1.4 mm at 72 h after treatment to 2.9 SD 1.5 mm
at 2 years. An additional 41% of the GSV became undetectable by ultrasound at 2-year follow
up. In two patients we observed re-opening of an initially closed GSV lumen. Neovascularisa-
tion was found in one RFO case and in four S and L cases. Cumulative rates of recurrent vari-
cose veins at combined 1 and 2 years follow-up were 14% for RFO and 21% for S and L (NS).
The difference in global QOL score in favour of RFO re-appeared at 1 year and remained signif-
icant at 2 years after treatment.blished in Eur J Vasc Endovasc Surg 2005;29:67e73.
, MD, PhD, Straub Foundation, Straub Clinic and Hospital, and University of Hawaii John A. Burns
.
(F. Lurie).
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S108 F. Lurie et al.Conclusion: The 2-year clinical results of radiofrequency obliteration are at least equal to those
after high ligation and stripping of the GSV. In the vast majority of RFO patients the GSV
remained permanently closed, and underwent progressive shrinkage to eventual sonographic
disappearance. Recurrence and neovascularisation rates were similar in the two groups although
limited patient numbers prevent reliable statistical analysis. Improved quality of life scores
persisted through the 2-year observations in the RFO group compared to the S and L group.
ª 2011 Published by Elsevier Ltd on behalf of European Society for Vascular Surgery.Figure 1 Study design.Introduction
Varicose veins is a common clinical problem which has
a significant effect upon quality of life.1 Reflux in the great
saphenous vein (GSV) is one of the most frequent causes of
primary chronic venous disease (CVD). This may progress to
cause patient disability if left untreated.2 The frequency of
varicose veins, which is increasing as the average age of the
population rises, makes this disease a significant public
health issue.
High ligation and stripping of the GSV (S and L) has been
found to be effective in the treatment of GSV incompe-
tence. This operation directly addresses the problem of the
incompetent GSV by removing it from the circulation.
Although long-term results of surgical treatment show
a high rate of recurrence,3e11 S and L has become a stan-
dard of care for patients with GSV insufficiency. Morbidity
associated with incisions and surgical removal of the vein,
and temporary post-surgical decline in the quality of life,
are the major drawbacks of S and L.1,12 Attempts to mini-
mise surgical trauma, and to preserve the GSV as a poten-
tial conduit by high ligation without removal of the vein,
have been shown to lead to even higher recurrence
rates.3,13 Failure to ligate all proximal tributaries of the
GSV is thought to be one of the major causes of recurrence
after stripping and high ligation.14 This concept has never
been proven by an appropriately designed study.
The recently developed technology of endovascular
obliteration of the GSV using temperature-controlled radi-
ofrequency energy (Closure(r) procedure) is aimed at
removing the vein from the circulation whilst minimising
the consequences for the patient. A multi-centre rando-
mised controlled trial (EVOLVeS) demonstrated the superi-
ority of the Closure procedure compared to vein stripping in
its impact on the quality of life, time of return to pre-
operative level of physical activity and time of return to
work (RTW).12 The original study design was limited to a 4-
month period after surgery, and therefore did not address
the question of mid- or long-term effect of the procedure
and of recurrence rate.
Reports of non-randomised case series of Closure
procedures demonstrated a low recurrence rate after 24
months.15e17 Ultrasound follow-up to 2 years demonstrated
that the GSV remains closed and that the proximal
tributaries maintain their patency and competence.16
These observations cannot be directly compared to repor-
ted results of vein stripping because of possible differences
in patient population, surgical techniques and clinical
settings. Follow-up of the patients enrolled in the EVOLVeS
study can reveal important information on the durability of
the Closure procedure, recurrence rates following both
treatments, and duration of their effect on quality of life.This report presents results of 1 and 2-year clinical and
ultrasound follow-up data and quality of life surveys in the
patients enrolled in the EVOLVeS study.
Materials and Methods
A detailed description of the EVOLVeS protocol, patient
selection criteria, and treatments has been published in our
initial report.12 Several important aspects of this study
deserve mention here.
A total of 85 patients entered the study with 45 patients
(46 limbs) allocated to radiofrequency obliteration (RFO)
and 40 patients to high ligation and stripping (S and L), and 79
patients (80 limbs) received treatment (Fig. 1). Recruitment
was terminated mainly due to reluctance on the part of
patients to be blindly allocated to one or other of the
treatment options. The treatment was randomly assigned
via an internet based central system for all of the five
participating sites (France-2, Austria-1, United States-2).
Each of the participating sites had obtained an approval
of Institutional Review Board or Ethics committee of the
institution. Patients gave their informed written consent
for inclusion in the study.
Individuals with symptomatic varicose veins and incom-
petence of the great saphenous vein confirmed by duplex
ultrasound examination who were candidates for conven-
tional vein stripping were eligible for inclusion in the study.
During each patient’s visit a standard set of information
was collected. Physicians assessed patient’s signs and
EVOLVeS: Two-year Follow-up S109symptoms utilising venous clinical severity score (VCSS),18
and completed CEAP classification. They assessed patient’s
limbs for the presence of recurrent varicose veins. Ultra-
sound examination included measuring the external
(adventitia-to-adventitia) and internal (intima-to-intima)
diameters of the great saphenous vein (GSV) and character-
istics of outflow and reflux. In addition, each patient
completed the 20-question CIVIQ2 quality of life question-
naire that has been validated for use in patients with chronic
venous disease.19,20 In the analysis, each of the dimension
scores, and the global scores, were transformed into a scale
of 0-100.19 Zero represents the least possible impact on daily
activities andwell being, i.e. highest quality of life,while 100
represents a maximum negative impact.
The only difference between the two groups was in
treatment of the GSV. Both RFO and S and L were per-
formed in the great saphenous vein from the knee, or upper
calf, to the sapheno-femoral junction. Adjunctive proce-
dures on varices and perforators were limited to below-the-
knee sites in order to avoid confusion post-operatively
between morbidity due to the saphenous vein treatment of
the Closure procedure versus stripping and that due to the
adjunctive procedure.
Post-operative visits were at 72 h, 1 week, 3 weeks, 4
months, 1 and 2 years (Fig. 1). At 1 and 2 years follow-up
additional information was collected. The presence of
neovascularisation in the groin was assessed by duplex
ultrasound examination. This was defined as multiple small
vessels in the groin reconnecting more proximal vein or its
tributaries and the distal patent vein below the site of
interruption (S and L) or occlusion (RFO). In cases where
varicose veins were present, the question of whether
varicosities were new or pre-existing was considered. New
varicose veins below the knee were classified as recurrent
varicosities. Special attention was paid to visualisation of
the GSV after RFO to detect recanalisation of this vein. In
many cases the GSV was completely obliterated by the
treatment and could not be identified on ultrasound.
The patient records were reviewed by the sponsor for
completion of the study data points. After the data acqui-
sition the investigators conducted a thorough audit of the
raw data handling and storage methods, the data process-
ing accuracy, and the presentation of the specific results.
This was done twice, once after completion of 4-month
follow-up (LK and FL), and again after completion of 2-year
follow-up (RLK and FL). They reported that all of these
were in order, and that the results accurately reflected the
raw data received from the investigator sites. The sponsor,
VNUS Medical Technologies, Inc. provided support limited
to these functions, but did not interfere with the analysis of
the data or the formulation of the conclusions.Figure 2 External (adventitia-to-adventitia) GSV diameter
change in 20 RFO extremities in which GSV is still identifiable
by ultrasound at 2-year follow-up.Statistical methods
Student’s t-test, and one-way ANOVA with Tukey-Kramer
tests were used to analyse differences between the groups.
The Mann-Whitney U test was utilised where appropriate.
Differences were considered significant at the 95% level
(p < 0.05). When comparisons were made between
the score before treatment (baseline) and the score
after treatment, repeated measures ANOVA was used.Alternatively, the absolute difference between the
baseline score and the score after treatment for each
individual patient was used (such as in Fig. 6). The Cochran-
Mantel-Haenszel and Chi-square statistics were used for
comparing the frequencies. Kaplan-Meier analysis and Long
Rank test were used for analysis of time-series. All values
presented as the mean and standard deviation (SD); the 95%
confidence interval (CI) is also included where appropriate.Results
The first 4 months of follow-up revealed an advantage of
RFO in impact on quality of life, earlier return to usual level
of physical activity (RTA) and earlier RTW. There were no
major complications in either group. An important question
at the time of the initial study was rate of the technical
success of the Closure technique, mainly because it was
a relatively new procedure. Immediate intra-operative
success was reported in all but two cases.
Four months after Closure treatment four extremities
demonstrated reflux in the proximal GSV. The lengths of
refluxing segments were 4,22,28 and 30 cm. At 2-year
follow-up one of these extremities had a closed GSV with no
flow, another extremity exhibited the same length (4 cm) of
open GSV segment but no reflux, and in the remaining two
extremities the GSV remained open and incompetent.
In two patients we observed re-opening of an initially
closed GSV lumen. In both cases the GSV remained closed at
4 months, but at 2-year follow-up a competent segment of
GSV 23 cm long was found in one case, and a 34 cm long
incompetent GSV segment was found in another case. In
three S and L cases, open incompetent segments of
saphenous vein were found in the immediate vicinity of
original GSV location at the 2-year follow-up.
For the veins occluded by RFO, 51% of the GSV trunks
showed a continuing decrease in diameter during the period
of observation. Duplex ultrasonography showed that the
external (adventitia-to adventitia) diameter of obliterated
GSV decreased from a mean of 6.3 SD 1.4 mm 72 h after
surgery to 2.9 SD 1.5 mm 2 years later (p < 0.00001; Fig. 2).
An additional 41% of the GSVs became undetectable on
Figure 3 Cumulative prevalence of varicosities (Kaplan-
Meier analysis).
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decreased in size, but did not completely disappear were
initially larger compared to those that became sono-
graphically invisible. At 72 h after treatment their mean
external diameters were 6.3 SD 1.4 mm and 4.3 SD 1.4 mm
(p Z 0.0005) respectively. The rate of diameter decrease
was not significantly different in these groups (1.8 SD
0.9 mm/year and 2.2 SD 0.7 mm/year, pZ 0.085). In three
cases the GSV diameter did not change. Neovascularisation
was observed in one RFO case and in four S and L cases.
Cumulative rates of recurrent varicose veins at
combined 1 and 2 years follow-up were 14.3% for RFO and
20.9% for S and L (p > 0.05 Long Rank test, Fig. 3).
Theclinical courseof thediseasewassimilar inbothgroups
following treatment (Table 1). At the 2-year follow up, 12
patients (33%) after RFO and 8 patients (28%) after S and L had
no sign of venous disease (CEAP clinical class C0). A statisti-
cally significant difference in VCSS score between the groups
was observed at 72 h and 1 week after treatment (Fig. 4).
This disappeared at all subsequent follow-up assessments.
Major differences between RFO and S and L groups at
early follow-up were in time to return to usual levels of
physical activity, time to RTW, and quality of life (QOL).12
Although the difference in global QOL score was not
significant at 3 weeks after treatment, it surprisingly re-
appeared at 1 year and remained significant at 2 years
after treatment (Fig. 5). Pain was the only QOL dimension
consistently reduced in the RFO group throughout all
subsequent follow up both in absolute score and in change
from the pre-treatment value (Fig. 6).
Discussion
Our earlier report showed advantage for RFO compared to
S and L in the early follow-up period. These findings
were consistent with observations of non-randomised
studies.15e17 The remaining question was the durability of
the results. The fact that RFO violates two principles of
a mainstream paradigm for surgical treatment of GSV
reflux by leaving an open proximal segment of GSV and byleaving untouched the proximal GSV tributaries generated
reasonable scepticism regarding long-term results.21
Particular concern is the role of proximal tributaries in
development of recurrent varicose veins.
Publications on the surgical treatment of GSV reflux
provide the basis for questioning the role of proximal
tributaries in development of recurrences. The majority of
recurrent varicosities are located below the knee.6 In
a series of 264 limbs with recurrences 24.3 SD 12.5 year
after surgery, Jiang et al. showed that the source of
recurrence was confined to the groin in only 13.6%, and
incompetent groin tributaries were present only in 12% of
cases.8 In a detailed ultrasound study Labropoulos et al.
reported that in 65% of recurrences following stripping the
GSV, the source of recurrence was other than in the groin.
The clinical dynamics of primary chronic venous disease
after surgical treatment have not been studied sufficiently
to separate changes associated with surgery from those
caused by natural history. Published reports suggest that
new varicose veins can develop regardless of presence or
absence of a refluxing GSV.22
In this study, the recurrence rate was numerically lower
in the RFO group compared to the S and L group, but the
difference did not reach the level of statistical significance
due to insufficient numbers in our series. In three of five
cases of recurrent veins in the RFO group a segment of thigh
GSV was either not closed or re-opened. The likelihood of
recurrencewas 4.5 times higher in extremitieswith openGSV
segments compared to extremities with a successful Closure
treatment. This difference, however, did not reach the
level of statistical significance (ORZ 4.5, 95% CIZ 0.7e28).
Although our study was not powered to address these ques-
tions, the detected magnitude of differences between RFO
and S and L groups and between extremities with perma-
nently closed GSV and those with open GSV segments was
substantial. This justifies further investigation of recurrent
varicosity rates following both treatments, and with regard
to status of the GSV.
Some experts have expressed the opinion that because
the process of neovascularisation is associated with a groin
incision, RFO may lead to a much less frequent neo-
vascularisation compared to S and L.23
In our 2-year follow up of the EVOLVeS trial patients,
neovascularisation was observed in four S and L patients
and in one RFO patient. The numbers are too small to make
a statement about the difference, but it is seen that neo-
vascularisation can occur after RFO. It is important to
mention here that the only case of neovascularisation after
RFO occurred in a patient with initial technical failure, and
the GSV remained open and incompetent during 2 years of
observation.
Whether it is new vessels, or incompetent tributaries,
they need to be connected to a remaining segment of GSV
to cause clinical problems.10 In all but five cases in this
study, the lumen of the GSV was permanently closed at 2
years. Two of these five cases resulted from unsuccessful
procedures (technical failures),12 one was reported closed
immediately after procedure but appeared open at 72 h
after treatment, and in another two cases the GSV lumen
re-opened during follow up (6%).
Although the issues of recurrence or neovascularisation
are important, the EVOLVeS trial protocol was not designed
Figure 4 Changes in VCSS score. P-values are based on Mann-
Whitney U-test.
Table 1 Maximal clinical class (‘C’ of ‘CEAP’) before treatment and during follow-up.
Maximal
Clinical class
RFO (% of
observed extremities)
S&L (% of
observed extremities)
Pearson
Chi-Square
p
Before treatment C0 0 0 0.2 0.9
C1 0 0
C2 81.8 77.8
C3 9.1 11.1
C4 9.1 11.1
72 h C0 54.5 66.7 1.7 0.6
C1 25 13.9
C2 11.4 11.1
C3 0 0
C4 9.1 8.3
1 week C0 44.2 66.7 6.3 0.2
C1 37.2 16.7
C2 11.6 8.3
C3 0 2.8
C4 7 5.6
3 weeks C0 54.5 52.8 0.1 0.99
C1 27.3 30.6
C2 9.1 8.3
C3 0 0
C4 9.1 8.3
4 months C0 34.1 41.2 2.95 0.6
C1 38.6 32.4
C2 18.2 20.6
C3 0 2.9
C4 9.1 2.9
1 year C0 28 15 5.8 0.2
C1 56 40
C2 8 30
C3 0 5
C4 8 10
2 years C0 33.3 27.6 2.97 0.6
C1 41.7 31
C2 22.2 31
C3 0 3.4
C4 2.8 6.9
Figure 5 Global QOL score. P-values are based on Mann-
Whitney U-test.
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Figure 6 Change in pain QOL score compared to pre-
treatment value. Negative values reflect decrease in quality
of life. P-values are based on Mann-Whitney U-test.
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the two treatment groups. The results showed absence of
significant differences between RFO and S and L patients at
2 years after treatment. It has been suggested that the
pathological events leading to recurrence usually take
place within 2 years and do not change thereafter.7 In
combination with our finding of progressive shrinkage and
disappearance of the GSV trunk, this gives us confidence
that our results can be expected to be maintained for
a longer time than we have so far studied. As time prog-
resses clinical changes are more likely to reflect the natural
progression of disease than the difference in treatment
techniques.
This study is also in line with published observations of
changes in patients’ quality of life after treatment. Major
changes in QOL can be observed within 6 months after
surgery and lesser change thereafter.1
One of the limitations of this study is that selection of
the patients was based on indications for RFO that existed
at the time of study initiation (2000). At the present time
indications for RFO are much broader, which put the limits
of generalisation of this study under question. However the
same selection criteria were used for both RFO and S and L
groups, so the results of comparison between the two
treatments should be applicable to a broader population.
A 2-year clinical follow up of patients from the EVOLVeS
trial showed that the results of radio- frequency oblitera-
tion were at least equal to those after high ligation and
stripping of the great saphe- nous vein. Ultrasound follow-
up demonstrated that in the vast majority of RFO patients
the GSV remained permanently closed, and underwent
progressive shrinkage to eventual sonographic disappear-
ance. Recurrence and neovascularisation rates demon-
strated trends toward being lower after RFO compared to S
and L. Superior quality of life was demonstrated to be an
early advantage of RFO, and this has persisted throughout
the 2-year study period.
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